Non-carboxylated osteocalcin detection method and detection kit

By developing strong specificity non-carboxylated osteocalcin antibodies and related technical means, the problem of low sensitivity and complexity of detection of non-carboxylated osteocalcin in the prior art has been solved, and an efficient and highly specific detection method is achieved. for clinical application.

CN118909106AActive Publication Date: 2024-11-08BEIJING BARON MEDICAL EQUIP CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410294344.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-03-14
Publication Date
2024-11-08
Estimated Expiration
2044-03-14

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently and specifically detect non-carboxylated osteocalcin, and the existing methods are low in sensitivity, poor in repeatability, and are expensive to rely on imported reagents, which has problems such as radiocontamination or complex operation.

Method used

Developed a non-carboxylated osteocalcin antibody with strong specificity and high sensitivity and its use in detection, by designing heavy chain variable region CDR sequences and nucleic acid molecules, expression vectors, recombinant cells and immunoconjugates, Prepare kits and detection methods for specific detection of non-carboxylated osteocalcin.

Benefits of technology

It realizes high specificity and high sensitivity non-carboxylated osteocalcin detection, simplifies operation, reduces sample pretreatment requirements, is suitable for rapid and high-throughput detection, avoids contamination, and is suitable for clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909106A_ABST
    Figure CN118909106A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological detection. In particular to a non-carboxylated osteocalcin detection method and a detection kit. In the application, the antibody or the antigen binding fragment thereof comprises: a heavy chain variable region; the heavy chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 1-3 or an amino acid sequence with at least 80% identity with the amino acid sequence as shown in SEQ ID NO: 1-3. The antibody or the antigen binding fragment thereof can be used for specific detection of non-carboxylated osteocalcin. The detection kit prepared based on the antibody or the antigen binding fragment thereof can rapidly detect the content of the non-carboxylated osteocalcin in a serum or plasma sample, and is high in sensitivity, strong in specificity, simple to operate, low in pretreatment requirement on the sample, and suitable for rapid high-throughput detection of a large batch of samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biological detection, and specifically, relates to a detection method and a detection kit for non-carboxylated osteocalcin. Background Art

[0002] Osteocalcin (OC) is a non-collagenous bone matrix protein specifically synthesized and secreted by non-proliferative osteoblasts in bones. The precursor protein consists of a 23-amino acid signal peptide, a 28-amino acid propeptide and a 49-amino acid mature protein. In the post-expression modification stage, the signal peptide is hydrolyzed, and the propeptide recognition site binds to the carboxylase to carboxylate the Glu at positions 17, 21 and 24 to Gla, also known as bone γ-carboxyglutamate protein. The mature osteocalcin molecule contains 49 amino acids and has a molecular weight of about 5800 Da. Osteocalcin accounts for about 1% to 2% of the total protein in the human body, and its expression level is affected by age, gender and menopausal status. Osteocalcin has the effect of promoting bone mineralization and is an important component of the bone mineralization matrix. There are many types of OC in the blood, including uncarboxylated or decarboxylated osteocalcin, carboxylated fully osteocalcin and osteocalcin fragments. The determination of serum osteocalcin content can reflect both the activity of osteoblasts and the degree of bone turnover. The faster the bone renewal rate, the higher the OC value, and vice versa. Therefore, osteocalcin is used clinically as a common marker of bone renewal and can be used as a physiological indicator reflecting bone transformation.

[0003] Osteocalcin is also involved in the metabolism of energy such as sugar and fat. Under the acidification of the bone resorption process, the osteocalcin molecule loses the glutamic acid group, and its carboxylation degree decreases, increasing the content of incompletely carboxylated osteocalcin in the circulation. This incompletely carboxylated osteocalcin is considered to be an active endocrine hormone and a bridge for bones to participate in human endocrine regulation activities. Uncarboxylated osteocalcin can promote pancreatic cell proliferation and insulin expression, lower blood sugar levels, improve glucose tolerance and increase insulin sensitivity. It can also increase the content of adiponectin in the body and reduce serum triglycerides, thereby avoiding diet-induced obesity. Low-carboxylated osteocalcin can act on adipose tissue, inhibit liver glycogen synthesis, and then promote fatty acid oxidation in skeletal muscle and liver, increase the glucose intake of skeletal muscle to increase the sensitivity of peripheral tissues to glucose, which is of great significance for the study of currently common endocrine diseases such as obesity, diabetes and other metabolic syndromes. In addition, non-carboxylated osteocalcin can act on the testicles and interstitial cells, thereby promoting the biosynthesis of testosterone and affecting male reproduction.

[0004] Osteocalcin exists in two forms, carboxylated osteocalcin and non-carboxylated osteocalcin. It is difficult to screen antibodies with good specificity that can distinguish the two forms, which makes it difficult to determine the positive serum of non-carboxylated osteocalcin in clinical practice. Most of the diagnostic reagents for non-carboxylated osteocalcin in the industry rely on imports and are expensive.

[0005] Currently known methods for determining uncarboxylated osteocalcin include radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), latex-enhanced turbidimetry, etc. The radioimmunoassay has complicated steps, expensive reagents, requires the use of matching instruments, and has radioactive contamination. The enzyme-linked immunosorbent assay has the disadvantages of long detection time, complex operation, and poor repeatability. The latex-enhanced immunoturbidimetry has low sensitivity and poor repeatability of low values.

[0006] Currently, there is an urgent need to develop a highly specific and sensitive non-carboxylated osteocalcin antibody and a rapid quantitative detection method for non-carboxylated osteocalcin. Summary of the invention

[0007] The present application aims to solve one of the technical problems in the related art to a certain extent. To this end, the present application develops a non-carboxylated osteocalcin antibody with strong specificity and high sensitivity and the use of the antibody in the specific detection of non-carboxylated osteocalcin.

[0008] Specifically, this application provides the following technical solutions:

[0009] In the first aspect of the present application, the present application proposes an antibody or an antigen-binding fragment thereof. According to an embodiment of the present application, it comprises: a heavy chain variable region; the heavy chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% identity therewith. In some examples of the present application, the antibody or the antigen-binding fragment thereof can be used to specifically detect uncarboxylated osteocalcin.

[0010] In the second aspect of the present application, the present application proposes a nucleic acid molecule. According to an embodiment of the present application, the nucleic acid molecule encodes the antibody or antigen-binding fragment thereof described in the first aspect of the present application. In some examples of the present application, the antibody or antigen-binding fragment thereof encoded by the nucleic acid molecule can be used to specifically detect non-carboxylated osteocalcin.

[0011] In the third aspect of the present application, the present application proposes an expression vector. According to an embodiment of the present application, the expression vector carries the nucleic acid molecule described in the second aspect of the present application. In some examples of the present application, the expression vector can efficiently express the antibody or its antigen-binding fragment in a suitable host cell for specific detection of uncarboxylated osteocalcin or preparation of drugs related to uncarboxylated osteocalcin diseases.

[0012] In the fourth aspect of the present application, the present application proposes a method for preparing the antibody or antigen-binding fragment thereof described in the first aspect. According to an embodiment of the present application, the method comprises: introducing the expression vector described in the third aspect of the present application into a cell; culturing the cell under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof. In some examples of the present application, the antibody or antigen-binding fragment thereof can be prepared in large quantities in vitro by this method.

[0013] In the fifth aspect of the present application, the present application proposes a recombinant cell. According to an embodiment of the present application, the recombinant cell carries the antibody or antigen-binding fragment thereof described in the first aspect of the present application, the nucleic acid molecule described in the second aspect, or the expression vector described in the third aspect. In some examples of the present application, the recombinant cell can efficiently express the above-mentioned antibody or antigen-binding fragment thereof under appropriate conditions, and the antibody or antigen-binding fragment thereof can specifically bind to non-carboxylated osteocalcin.

[0014] In the sixth aspect of the present application, the present application proposes an immunoconjugate. According to an embodiment of the present application, the immunoconjugate comprises: the antibody or antigen-binding fragment thereof described in the first aspect of the present application, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, or the recombinant cell described in the fifth aspect. In some examples of the present application, the antibody or antigen-binding fragment can bind to non-carboxylated osteocalcin with high specificity and can be used to prepare a method for preventing and / or treating related diseases mediated by non-carboxylated osteocalcin.

[0015] In the seventh aspect of the present application, the present application proposes a composition. According to an embodiment of the present application, the composition includes: the antibody or antigen-binding fragment thereof described in the first aspect of the application, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, or the immunoconjugate of the sixth aspect. In some examples of the present application, the antibody or antigen-binding fragment thereof can bind to non-carboxylated osteocalcin with high specificity. In some examples of the present application, a composition comprising the antibody or antigen-binding fragment thereof, such as a food composition, a pharmaceutical composition, etc., also has a significant effect of treating and / or preventing related diseases mediated by non-carboxylated osteocalcin.

[0016] In the eighth aspect of the present application, the present application proposes the use of the antibody or its antigen binding fragment described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, the immunoconjugate of the sixth aspect, or the composition described in the seventh aspect in the preparation of a drug, and the drug is used to treat or prevent non-carboxylated osteocalcin-mediated related diseases. In some examples of the present application, the antibody or its antigen binding fragment can bind to non-carboxylated osteocalcin with high specificity. It is understandable that the drug comprising a series of substances such as the antibody or its antigen binding fragment also has a significant effect on treating or preventing non-carboxylated osteocalcin-mediated related diseases (such as osteoarthritis).

[0017] In the ninth aspect of the present application, the present application proposes a drug. According to an embodiment of the present application, the drug includes: the antibody or its antigen binding fragment described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fifth aspect, the immunoconjugate of the sixth aspect, or the composition described in the seventh aspect, and the drug is used to treat or prevent related diseases mediated by non-carboxylated osteocalcin. In some examples of the present application, the antibody or its antigen binding fragment can bind to non-carboxylated osteocalcin with high specificity. It is understandable that drugs containing a series of substances such as the antibody or its antigen binding fragment also have significant effects on treating or preventing related diseases mediated by non-carboxylated osteocalcin (such as bone and joint diseases).

[0018] In the tenth aspect of the present application, the present application proposes the use of the antibody or its antigen binding fragment described in the first aspect in the preparation of a kit for detecting non-carboxylated osteocalcin. In some examples of the present application, the antibody or its antigen binding fragment can bind to non-carboxylated osteocalcin with high specificity. Therefore, the kit comprising the antibody or its antigen binding fragment can be used for high specificity and high sensitivity detection of non-carboxylated osteocalcin.

[0019] In the eleventh aspect of the present application, the present application proposes a kit. According to an embodiment of the present application, the kit comprises the antibody or antigen-binding fragment thereof described in the first aspect. In some examples of the present application, the antibody or antigen-binding fragment thereof can bind to non-carboxylated osteocalcin with high specificity. In some scientific studies, the kit can be used for qualitative or quantitative detection of non-carboxylated osteocalcin protein in biological samples, and can also be used to judge the status of an individual, such as after obtaining the non-carboxylated osteocalcin level of the individual, judging whether the non-carboxylated osteocalcin level is higher or lower than the normal level.

[0020] In the twelfth aspect of the present application, the present application proposes a method for detecting non-carboxylated osteocalcin. According to an embodiment of the present application, the method comprises: using the kit described in the eleventh aspect of the present application to detect and process the sample to be tested, so as to determine the content of the non-carboxylated osteocalcin in the sample to be tested. In some examples of the present application, the above method is used for high-sensitivity detection of non-carboxylated osteocalcin, and is pollution-free to the environment, has strong specificity, is simple to operate, and has low sample pre-treatment requirements. In practical clinical applications, a large number of samples can be quickly and high-throughput detected with the aid of a chemiluminometer.

[0021] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The above and / or additional aspects and advantages of the present application will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0023] Figure 1 This is a schematic diagram of antibody subtype detection results according to an embodiment of the present application;

[0024] Figure 2 It is a schematic flow chart of the chemiluminescent immunoassay method for separating non-carboxylated osteocalcin by magnetic microparticles according to one embodiment of the present application. DETAILED DESCRIPTION

[0025] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.

[0026] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0027] In the present application, unless otherwise specified, the terms "comprise" or "include" are open expressions, that is, including the contents specified in the present application but not excluding other contents.

[0028] In this application, unless otherwise stated, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur.

[0029] In this application, unless otherwise specified, the terms "first" and "second" are used for descriptive purposes only and are not to be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of this application, "plurality" means at least two, such as two, three, etc., unless otherwise clearly and specifically defined.

[0030] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0031] In this application, unless otherwise specified, the term "antibody or antigen-binding fragment thereof" refers to a protein encoded by an animal gene and biosynthesized. In some examples of this application, the antibody is selected from a polyclonal antibody or a monoclonal antibody, and the antigen-binding fragment is selected from a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a F(ab)2 fragment, a Fv fragment, a scFv fragment, a scFv-Fc fusion protein, a scFv-Fv fusion protein or a minimum recognition unit.

[0032] Among them, the "monoclonal antibody (or monoclonal antibody)" mentioned above refers to an antibody that can only recognize one specific antigen epitope. Among them, the common monoclonal antibody includes two light chains with lighter molecular weight and two heavy chains with heavier molecular weight. The heavy chain (H chain) and the light chain (L chain) are connected by disulfide bonds to form a tetrapeptide chain molecule. The amino acid sequence of the amino terminal (N terminal) of the heavy chain or light chain varies greatly, which is called the variable region (V region). The carboxyl terminal (C terminal) of the heavy chain or light chain is relatively stable and varies very little, which is called the constant region (C region); the V region of the L chain and the H chain are called VL and VH respectively. Among them, the amino acid sequences of the variable regions between different antibodies are highly different (the amino acid sequences of other regions of the antibody are relatively highly identical), and are responsible for recognizing and binding to specific antigenic determinants. In the variable region of the antibody, the framework region and the CDR region (comlementarity determining region) can be further subdivided. A typical antibody variable region has 3 framework regions and 3 CDR regions (which are interspersed with each other). The framework region mainly plays a role in forming the protein domain framework, while the CDR region mainly plays a role in antigen-antibody specific recognition and binding.

[0033] Among them, the "polyclonal antibody (or polyclonal antibody)" mentioned above refers to an antibody that can recognize multiple antigenic epitopes, such as an antibody that can recognize two antigenic epitopes (referred to as double antibody), an antibody that can recognize three antigenic epitopes, or an antibody that can recognize four antigenic epitopes. It is understood in a broad sense and the specific structure is not limited as long as it can recognize multiple antigenic epitopes.

[0034] The "antigen-binding fragment" mentioned above refers to an antibody fragment that retains the ability to specifically bind to an antigen.

[0035] The "Fab fragment" mentioned above generally refers to an antibody fragment that binds to an antigen, which is composed of VH and CH1 of a heavy chain and a complete light chain, and the light chain and the heavy chain are connected by a disulfide bond.

[0036] Among them, the "Fv fragment" mentioned above usually refers to an antibody fragment composed only of a light chain variable region (VL) and a heavy chain variable region (VH) connected by non-covalent bonds, and is the smallest functional fragment in an antibody that retains a complete antigen binding site.

[0037] The "scFv fragment" referred to above refers to an antibody fragment formed by connecting the heavy chain variable region (VH) and the light chain variable region (VL) via a connecting peptide.

[0038] The "minimum recognition unit" mentioned above refers to an antibody consisting of only one CDR, and its molecular weight is very small, accounting for only about 1% of the complete antibody.

[0039] In the present application, unless otherwise specified, the amino acid sequences of the CDRs listed herein are shown in accordance with the IMGT definition rules. However, it is well known to those skilled in the art that the CDRs of antibodies can be defined in the art by a variety of methods, such as the Kabat rule, the Chothia rule, etc. It should be understood by those skilled in the art that, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or a region thereof (such as a variable region) should be understood to cover the complementary determining region defined by any of the above-mentioned known schemes described in the present invention. Although the scope of protection requested in the present application is based on the sequences shown in the IMGT definition rules, the amino acid sequences corresponding to the definition rules of other CDRs should also be included in the scope of protection of the present application.

[0040] As used herein, the "IMGT definition" refers to the new standardized numbering system introduced by Lefranc et al. for all protein sequences of the immunoglobulin superfamily, see Lefranc, et al., The Immunologist, 7, 132-136 (1999). The "Kabat definition" refers to the definition system described by Kabat et al., U. S. Pat. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). The "Chothia definition" refers to Chothia et al., J Mol Biol 196:901-917 (1987).

[0041] In this application, the abbreviations for amino acid residues are the standard three-letter and / or one-letter codes used in the art to refer to one of the 20 common L-amino acids, and have the following meanings: A: Ala (alanine); R: Arg (arginine); N: Asn (asparagine); D: Asp (aspartic acid); C: Cys (cysteine); Q: Gln (glutamine); E: Glu (glutamate); G: Gly (glycine); H: His (histidine); I: Ile (isoleucine); L: Leu (leucine); K: Lys (lysine); M: Met (methionine); F: pHe (phenylalanine); P: Pro (proline); S: Ser (serine); T: Thr (threonine); W: Trp (tryptophan); Y: Tyr (tyrosine); V: Val (valine).

[0042] In this application, the term "identity" is used to describe an amino acid sequence or a nucleic acid sequence relative to a reference sequence, and the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in MolecμLar Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 48:443); the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:24 ... .70:173-187 (1997); and BLASTP, BLASTN, and BLASTX algorithms (see Altsch μL et al. (1990) J. Mol. Biol. 215:403-410). Computer programs that utilize these algorithms are also available, and include, but are not limited to: ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altsch μL et al., Meth. Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altsch μL et al., supra, FASTA, and TFASTA, available in the Genetics Computing Group (GCG) package, Version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0043] In the present application, under the premise of not substantially affecting the activity of the antibody (retaining at least 95% of the activity), those skilled in the art may replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present application to obtain a variant of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The variant sequence described in the present application may have at least 80% identity (or homology) with the reference sequence, which means at least 80% with each reference sequence, which may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity. The sequence consistency described in the present application can be measured using sequence analysis software. For example, the computer program BLAST, especially BLASTP or TBLASTN, with default parameters is used. The amino acid sequences described in the present invention are all shown in the manner of N-terminus to C-terminus.

[0044] In this application, unless otherwise indicated, the term "conservative amino acid substitution" refers to the replacement of an amino acid with another amino acid residue that is biologically, chemically or structurally similar. Biologically similar means that the replacement does not destroy the biological activity of the non-carboxylated osteocalcin antibody or the non-carboxylated osteocalcin antigen. Structurally similar means that the amino acids have side chains of similar length, such as alanine, glycine or serine, or have side chains of similar size. Chemical similarity means that the amino acids have the same charge or are both hydrophilic or hydrophobic. For example, the hydrophobic residues isoleucine, valine, leucine or methionine replace each other. Or with polar amino acids, such as arginine replacing lysine, glutamic acid replacing aspartic acid, glutamine replacing asparagine, serine replacing threonine, etc.

[0045] In one aspect of the present application, the present application proposes an antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region; a heavy chain variable region CDR sequence having an amino acid sequence as shown in SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% identity thereto. In some examples of the present application, the antibody or the antigen-binding fragment thereof can be used to specifically detect uncarboxylated osteocalcin. The amino acid sequence is shown in Table 1.

[0046] In some examples of the present application, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region CDR1 sequence as shown in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity with SEQ ID NO: 1. In a specific example of the present application, the heavy chain variable region CDR1 sequence of the antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 1. In some examples of the present application, the heavy chain variable region CDR1 sequence as shown in SEQ ID NO: 1 is used, and the affinity and specificity of the antibody are higher.

[0047] In some examples of the present application, the antibody or its antigen-binding fragment comprises: a heavy chain variable region CDR2 sequence as shown in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity with SEQ ID NO: 2. In a specific example of the present application, the heavy chain variable region CDR2 sequence of the antibody or its antigen-binding fragment is as shown in SEQ ID NO: 2. In some examples of the present application, the heavy chain variable region CDR2 sequence as shown in SEQ ID NO: 2 is used, and the affinity and specificity of the antibody are higher.

[0048] In some examples of the present application, the antibody or its antigen-binding fragment comprises: a heavy chain variable region CDR3 sequence as shown in the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 80% identity with SEQ ID NO: 3. In a specific example of the present application, the heavy chain variable region CDR3 sequence of the antibody or its antigen-binding fragment is as shown in SEQ ID NO: 3. In some examples of the present application, the heavy chain variable region CDR3 sequence as shown in SEQ ID NO: 3 is used, and the affinity and specificity of the antibody are higher.

[0049] In some examples of the present application, the antibody or its antigen-binding fragment further includes: a light chain variable region; the light chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 4 to 6 or an amino acid sequence having at least 80% identity thereto.

[0050] In some examples of the present application, the antibody or its antigen-binding fragment comprises: a light chain variable region CDR1 sequence as shown in the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 80% identity with SEQ ID NO: 4. In a specific example of the present application, the light chain variable region CDR1 sequence of the antibody or its antigen-binding fragment is as shown in SEQ ID NO: 4. In some examples of the present application, the light chain variable region CDR1 sequence as shown in SEQ ID NO: 4 is used to achieve highly specific binding and recognition of different antigens by the antibody through synergistic action with the heavy chain variable region.

[0051] In some examples of the present application, the antibody or its antigen-binding fragment comprises: a light chain variable region CDR2 sequence as shown in the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence having at least 80% identity with SEQ ID NO: 5. In a specific example of the present application, the light chain variable region CDR2 sequence of the antibody or its antigen-binding fragment is shown in SEQ ID NO: 7. In some examples of the present application, the light chain variable region CDR2 sequence as shown in SEQ ID NO: 5 is used to achieve highly specific binding and recognition of different antigens by the antibody through synergistic action with the heavy chain variable region.

[0052] In some examples of the present application, the antibody or its antigen-binding fragment comprises: a light chain variable region CDR3 sequence as shown in the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having at least 80% identity with SEQ ID NO: 6. In a specific example of the present application, the light chain variable region CDR3 sequence of the antibody or its antigen-binding fragment is as shown in SEQ ID NO: 6. In some examples of the present application, the light chain variable region CDR3 sequence as shown in SEQ ID NO: 6 is used to achieve highly specific binding and recognition of different antigens by the antibody through synergistic action with the heavy chain variable region.

[0053] In some examples of the present application, the antibody or antigen-binding fragment thereof further contains a heavy chain framework region sequence, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody, or a mutant thereof. In some examples of the present application, antibodies containing a framework region help increase the structural stability of the antibody.

[0054] In some preferred examples of the present application, at least a portion of the heavy chain framework region sequence is derived from a murine antibody.

[0055] In some examples of the present application, the heavy chain variable region amino acid sequence is shown in SEQ ID NO:7.

[0056] In some examples of the present application, the antibody or its antigen-binding fragment amino acid sequence has one or more conservative amino acid substitutions compared to SEQ ID NO: 7. Optionally, two or three conservative amino acid substitutions. Of course, these conservative amino acid substitutions will not change the biological function of the antibody or antigen-binding fragment. In some specific examples of the present application, these conservative amino acid substitutions may occur in amino acids other than the CDR region in the heavy chain variable region and the light chain variable region.

[0057] In some examples of the present application, the antibody or antigen-binding fragment thereof further contains a light chain framework region sequence, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody, or a mutant thereof. In some examples of the present application, antibodies containing a framework region help increase the structural stability of the antibody.

[0058] In some examples of the present application, the light chain variable region amino acid sequence is shown in SEQ ID NO:8.

[0059] In some examples of the present application, the antibody or antigen-binding fragment thereof further contains a heavy chain constant region, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody, or a mutant thereof. By adding the constant region sequence, it helps to maintain the structural stability of the entire antibody molecule.

[0060] In some examples of the present application, at least a portion of the heavy chain constant region sequence is from a murine antibody.

[0061] In some examples of the present application, the heavy chain constant region amino acid sequence is shown in SEQ ID NO:9.

[0062] In some examples of the present application, the antibody or antigen-binding fragment thereof further contains a light chain constant region sequence, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody, or a mutant thereof. By adding the constant region sequence, it helps to maintain the structural stability of the entire antibody molecule.

[0063] In some examples of the present application, the light chain constant region is selected from a murine antibody.

[0064] In some examples of the present application, the light chain constant region amino acid sequence is shown in SEQ ID NO:10.

[0065] In some examples of the present application, the antibody includes at least one selected from a polyclonal antibody and a monoclonal antibody; or the antigen-binding fragment includes at least one selected from a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a F(ab)2 fragment, a Fv fragment, a scFv fragment, a scFv-Fc fusion protein, a scFv-Fv fusion protein, and a minimum recognition unit. In some preferred examples of the present application, the antibody is a monoclonal antibody.

[0066] It should be noted that any of the antibodies exemplified above in the present application can be directly synthesized based on the antibody variable region amino acid sequence provided in the present application. In addition, different antibody analogs can be derived through further chemical modification.

[0067] In another aspect of the present application, the present application provides an antibody analog, which comprises the antibody or antigen-binding fragment thereof as exemplified above.

[0068] It should be noted that the antibody analogs mentioned in the specification and claims of this application refer to derivatives produced by biological or chemical methods, which are obtained by deleting, adding, or modifying chemical groups (such as amino acids) on the basis of the antibody structure. These derivatives still contain structures similar to the antibody variable region (or the CDR region in the antibody variable region), and can produce reactions similar to antigen-antibody binding through these structures.

[0069] In another aspect of the present application, the present application proposes a nucleic acid molecule encoding an antibody or an antigen-binding fragment thereof of any of the aforementioned examples. In some examples of the present application, the antibody or antigen-binding fragment thereof encoded by the nucleic acid molecule can be used to specifically detect uncarboxylated osteocalcin.

[0070] In some examples of the present application, the nucleic acid molecule is DNA.

[0071] It should be noted that, for the nucleic acid molecules mentioned in the specification and claims of this application, those skilled in the art should understand that they actually include any one or both of the complementary double strands. For convenience, in this specification and claims, although only one strand is given in most cases, the other strand complementary thereto is actually disclosed. In addition, the nucleic acid sequence in this application includes DNA form or RNA form, and disclosing one of them means that the other is also disclosed.

[0072] The nucleotide sequences of the nucleic acid molecules mentioned in this application can be obtained by techniques known to those skilled in the art, and can also be species optimized to make them easier to express in mammalian cells.

[0073] In another aspect of the present application, the present application proposes an expression vector, which carries any of the aforementioned exemplified nucleic acid molecules. In some examples of the present application, the expression vector can efficiently express an antibody or an antigen-binding fragment thereof in a suitable host cell for specific detection of uncarboxylated osteocalcin or preparation of a drug related to an uncarboxylated osteocalcin disease.

[0074] It should be noted that when the above-mentioned nucleic acid molecules are connected to the vector, the nucleic acid molecules can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecules. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecules can be operably connected to the control elements. Herein, "operably connected" means that the exogenous gene is connected to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their expected functions of regulating the transcription and translation of the exogenous gene. Commonly used vectors can be, for example, plasmids, bacteriophages, etc., such as pcDNA plasmids.

[0075] In another aspect of the present application, the present application proposes a method for preparing any of the aforementioned examples of antibodies or antigen-binding fragments thereof, comprising: introducing any of the aforementioned examples of expression vectors into cells; culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof. In some examples of the present application, the antibody or antigen-binding fragment thereof can be prepared in large quantities in vitro by this method.

[0076] In some examples of the present application, the cell is a eukaryotic cell. In some specific examples of the present application, the eukaryotic cell is a mammalian cell, such as a 293F cell, a CHO cell, etc. When the cell is a mammalian cell, the expression efficiency of the antibody or its antigen-binding fragment is higher.

[0077] It should be noted that eukaryotic cells do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0078] In another aspect of the present application, the present application proposes a recombinant cell carrying any of the above-mentioned antibodies or antigen-binding fragments thereof, nucleic acid molecules or expression vectors. In some examples of the present application, the recombinant cell is obtained by transfecting or transforming the expression vector, and the recombinant cell can efficiently express the above-mentioned antibody or antigen-binding fragment thereof under appropriate conditions, and the antibody or antigen-binding fragment thereof can specifically bind to non-carboxylated osteocalcin.

[0079] It should be noted that the recombinant cells of the present application are not particularly limited and can be prokaryotic cells, eukaryotic cells or bacteriophages. Prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. Eukaryotic cells can be fungi including Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces, Trichoderma, insect cells such as Sphaerotheca serrata, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc. In certain embodiments, the recombinant cells of the present application are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0080] It should be noted that the "suitable conditions" in the specification of this application refer to conditions suitable for the expression of the antibody or its antigen-binding fragment of the present application. It is easy for those skilled in the art to understand that conditions suitable for the expression of recombinant antibodies include but are not limited to suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of recombinant antibodies according to the specific environment of the laboratory.

[0081] In another aspect of the present application, the present application provides a hybridoma cell. The hybridoma cell can produce any of the above-mentioned antibodies or antigen-binding fragments thereof.

[0082] In some examples of the present application, the hybridoma cells can be produced by classical methods for preparing monoclonal antibodies.

[0083] In the classic monoclonal antibody preparation method, first of all, a suitable antigen is required to be available and used to immunize animals. In order to prepare anti-uncarboxylated osteocalcin antibodies (or antibody analogs), the suitable antigen must contain uncarboxylated osteocalcin. This antigen can be obtained by separation and purification from natural human tissue or blood, chemical synthesis, or a combination of these methods, and used for animal immunization and antibody screening detection.

[0084] Exemplarily, in the classical monoclonal antibody preparation method, first, an animal is immunized with a non-carboxylated osteocalcin antigen, and blood is collected at intervals to verify whether the animal has produced an antibody response to the non-carboxylated osteocalcin antigen. Then, B cells are isolated from the spleen of an animal with an antibody response, and fused with immortal myeloma cells in vitro to obtain hybridoma cells. These hybridoma cells are then diluted to the limit in a culture plate and regrown (monoclonal hybridoma cell strains), and the culture supernatant of these hybridoma cell strains is taken to detect whether it contains specific antibodies against the antigen. According to the antibody yield, quality and cell strain growth characteristics, the best monoclonal antibody production cell strain can be selected for subsequent monoclonal antibody production.

[0085] Other methods can also be used to obtain monoclonal antibodies. For example, spleen cells from the above animals can be isolated and then incubated with labeled antigens (such as fluorescein-labeled non-carboxylated osteocalcin). Since antibody-producing B cells usually have antibody molecules presented on the cell membrane surface, these cells will be bound (stained) by the labeled antigen and can be sorted by a fluorescent flow cytometer. The mRNA of these sorted B cells can be isolated, and a library of antibody variable region cDNAs can be obtained by in vitro reverse transcription and specific PCR reactions. This cDNA library can be inserted into an expression plasmid (such as an antibody expression plasmid suitable for expression in mammalian cells, or a phage expression plasmid suitable for expression in bacterial cells) and expressed in a host cell suitable for this expression plasmid. These host cells (or phages) can be isolated and purified (cloned) by different methods (such as the cell limiting dilution culture method described above, or the phage plaque plating method). These cell lines or phage clones can be used to produce antibodies and analyze and identify the antibodies.

[0086] In some preferred examples of the present application, multiple subcutaneous injections at multiple points are used during the animal immunization process, thereby increasing the titer of the final animal serum and the positive clone rate.

[0087] In some preferred examples of the present application, the inventors postponed the addition of HAT screening reagent from the day of fusion to the second day, which significantly improved the cell positivity rate.

[0088] In some preferred examples of the present application, the inventors selected a variety of uncarboxylated osteocalcin structural analogs to compare antibody specificity detection. After multiple rounds of screening, antibodies with good specificity for uncarboxylated osteocalcin were obtained (sequences shown in Table 1).

[0089] The non-carboxylated osteocalcin antibody of the present application can be used to detect non-carboxylated osteocalcin in human serum or body fluids, or substances containing non-carboxylated osteocalcin, and substances that can specifically bind to non-carboxylated osteocalcin (such as non-carboxylated osteocalcin antibodies). The principle of detection is mainly based on the specific recognition and binding of the non-carboxylated osteocalcin antibody of the present application to non-carboxylated osteocalcin, and is detected using chemical labeling technology (such as labeled antibodies, or labeled specific secondary antibodies) or physical detection technology (such as light scattering technology, plasma resonance technology, etc.).

[0090] In another aspect of the present application, the present application proposes an immunoconjugate, comprising: any of the above-mentioned antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors or recombinant cells. In some examples of the present application, the antibody or antigen-binding fragment can bind to uncarboxylated osteocalcin with high specificity and can be used to prepare a method for preventing and / or treating related diseases mediated by uncarboxylated osteocalcin.

[0091] In some examples of the present application, the immunoconjugate may further include a therapeutic agent, wherein the therapeutic agent is selected from at least one of a cytokine, an immunomodulator, and a small molecule drug.

[0092] In another aspect of the present application, the present application proposes a composition, including: an antibody or its antigen-binding fragment, a nucleic acid molecule, an expression vector, a recombinant cell or an immunoconjugate of any of the aforementioned examples. In some examples of the present application, the antibody or its antigen-binding fragment can bind to non-carboxylated osteocalcin with high specificity. In some examples of the present application, a composition comprising an antibody or its antigen-binding fragment, such as a food composition, a pharmaceutical composition, etc., also has a significant effect of treating and / or preventing related diseases mediated by non-carboxylated osteocalcin.

[0093] It should be noted that the composition includes combinations separated in time and / or space, as long as they can work together to achieve the purpose of the present invention. For example, the components contained in the composition can be administered to the subject as a whole, or separately. When the components contained in the composition are administered to the subject separately, each component can be administered to the subject simultaneously or sequentially.

[0094] In another aspect of the application, the application proposes the use of the antibody or its Fab, nucleic acid molecule, expression vector, recombinant cell, immunoconjugate or composition of any of the aforementioned examples in the preparation of medicines, and the medicines are used to treat or prevent the related diseases mediated by non-carboxylated osteocalcin. In some examples of the application, the antibody or its Fab can bind to non-carboxylated osteocalcin with high specificity. In some examples of the application, the antibody or its Fab can bind to non-carboxylated osteocalcin with high specificity. It is understandable that the medicine comprising a series of substances such as antibodies or their Fabs also has a significant effect on the treatment or prevention of related diseases mediated by non-carboxylated osteocalcin (such as osteoarthritis).

[0095] In some examples of the present application, non-carboxylated osteocalcin-mediated related diseases include liver disease, diabetes, rheumatoid arthritis, hypoparathyroidism, peripheral arterial and coronary sclerosis, bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity and bone tumors.

[0096] In another aspect of the application, the application proposes a medicine, including: an antibody or its antigen binding fragment, a nucleic acid molecule, an expression vector, a recombinant cell, an immunoconjugate or a composition of any of the aforementioned examples, which is used to treat or prevent non-carboxylated osteocalcin-mediated related diseases. In some examples of the application, the antibody or its antigen binding fragment can bind non-carboxylated osteocalcin with high specificity. It is understandable that medicines comprising a series of substances such as antibodies or their antigen binding fragments also have significant effects on the treatment or prevention of non-carboxylated osteocalcin-mediated related diseases (such as osteoarthritis).

[0097] In some examples of the present application, the drug includes a pharmaceutically acceptable carrier and an effective amount of an antibody active ingredient.

[0098] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.

[0099] As used herein, "pharmaceutically acceptable" ingredients are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), i.e., substances with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.

[0100] The drug of the present application contains a safe and effective amount of the active ingredient of the present application and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the drug preparation should match the mode of administration. The dosage form of the drug of the present application is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The drug is preferably manufactured under sterile conditions.

[0101] The effective amount of the active ingredient of the present application may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment condition, several divided doses may be given per day, or the dose may be reduced proportionally.

[0102] The pharmaceutically acceptable carriers of the present application include, but are not limited to, water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.

[0103] In another aspect of the present application, the present application proposes the use of the antibody or its antigen binding fragment of any of the aforementioned examples in the preparation of a kit, and the kit is used to detect non-carboxylated osteocalcin. In some examples of the present application, the antibody or its antigen binding fragment can bind to non-carboxylated osteocalcin with high specificity. Therefore, the kit comprising the antibody or its antigen binding fragment can be used for high specificity and high sensitivity detection of non-carboxylated osteocalcin.

[0104] In another aspect of the present application, the present application proposes a kit, comprising an antibody or an antigen-binding fragment thereof of any of the aforementioned examples. In some examples of the present application, the antibody or its antigen-binding fragment has high sensitivity and specificity in detecting non-carboxylated osteocalcin protein. In addition, the kit can be used in conjunction with a fully automatic chemiluminescence analyzer, greatly simplifying the operating steps, increasing the detection speed and detection flux, improving the detection efficiency, and avoiding errors caused by human operation. The principle of combining chemiluminescence detection technology with magnetic microsphere immunoseparation technology is used to quantitatively detect the non-carboxylated osteocalcin content in human serum or plasma samples, ensuring the sensitivity of the detection. Due to the sandwich method used by the kit, there is no pollution, strong specificity, simple operation, and low requirements for sample pre-treatment, and large quantities of samples can be detected quickly and at high throughput, which is convenient for clinical reagent application. The kit provided by the present application provides a more accurate, precise, convenient, quick and simple method for clinical detection of non-carboxylated osteocalcin in human serum.

[0105] In some examples of the present application, the kit further includes: at least one of: magnetic microspheres, biomarkers, biomarker substrates, buffers, calibrators, and quality control products.

[0106] In some examples of the present application, the particle size of the magnetic microspheres is selected from 0.5-10 μm, preferably 3-8 μm, and optionally 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, or 10 μm.

[0107] In some examples of the present application, the biomarker includes at least one of a biological enzyme, a fluorescent marker, and a chemiluminescent marker.

[0108] In some examples of the present application, the biological enzyme is selected from at least one of horseradish peroxidase and alkaline phosphatase. In practical applications, the biological enzyme is compatible with the biomarker substrate, that is, the biological enzyme has the activity of catalyzing the luminescence of the biomarker substrate.

[0109] In some examples of the present application, the fluorescein is selected from at least one of fluorescein isothiocyanate, tetraethylrhodamine and tetramethylrhodamine isothiocyanate.

[0110] In some examples of the present application, the chemiluminescent label is selected from at least one of acridinium ester, terpyridine ruthenium, isoluminol or a derivative thereof.

[0111] In some examples of the present application, the buffer includes at least one selected from phosphate buffer, carbonate buffer, tris buffer and citrate buffer. The concentration of the buffer is selected from 10 to 100 mM, optionally 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM or 100 mM; the pH of the buffer is selected from 6.0 to 9.0, optionally 6.0, 7.0, 8.0 or 9.0.

[0112] In some examples of the present application, the calibrator comprises different concentration gradients of uncarboxylated osteocalcin.

[0113] In some examples of the present application, the quality control comprises a buffered solution of uncarboxylated osteocalcin at a defined concentration.

[0114] In another aspect of the present application, the present application proposes a non-carboxylated osteocalcin detection method, including: using the kit of any of the aforementioned examples to detect and process the sample to be tested, so as to determine the content of non-carboxylated osteocalcin in the sample to be tested. In some examples of the present application, the above method is used for high-sensitivity detection of non-carboxylated osteocalcin, and is pollution-free to the environment, has strong specificity, is simple to operate, and has low pre-treatment requirements for samples. In practical clinical applications, large batches of samples can be detected by rapid high-throughput detection with the aid of a chemiluminometer. According to the detection method of an embodiment of the present invention, it can be used for non-clinical diagnosis purposes, such as when the research and development personnel want to screen the intervention factor of non-carboxylated osteocalcin, the intervention factor to be screened can be applied to the sample to be tested, and the content of non-carboxylated osteocalcin in the sample to be tested changes before and after the intervention factor is detected according to the method of an embodiment of the present invention, to judge the target non-carboxylated osteocalcin intervention factor.

[0115] In some examples of the present application, the detection process includes: coupling the magnetic microspheres with the first antibody to obtain a first antibody complex; labeling the second antibody with a biomarker to obtain a second antibody complex; mixing the sample to be tested, the first antibody complex and the second antibody complex; contacting the mixed treatment product with a biomarker substrate, the biomarker having the activity of catalyzing the luminescence of the biomarker substrate; determining the content of uncarboxylated osteocalcin in the sample to be tested based on the luminescence intensity obtained after the contact treatment. Wherein, the first antibody and the second antibody independently recognize uncarboxylated osteocalcin and osteocalcin, respectively. It can be understood that the first antibody is selected from an antibody that recognizes uncarboxylated osteocalcin, and the second antibody is selected from an antibody that recognizes osteocalcin; or the first antibody is selected from an antibody that recognizes osteocalcin, and the second antibody is selected from an antibody that recognizes uncarboxylated osteocalcin. The present application adopts an immune sandwich method to realize the detection of uncarboxylated osteocalcin. Therefore, the first antibody and the second antibody should avoid being the same to prevent the two antibodies from recognizing the same antigenic epitope, thereby causing the detection to fail.

[0116] In some examples of the present application, the antibody that recognizes uncarboxylated osteocalcin is derived from the antibody or antigen-binding fragment thereof of any example of the present application.

[0117] In some examples of the present application, the antibody that recognizes osteocalcin is from a commercial osteocalcin antibody, such as R&D Systems, Inc., catalog number MAB11327.

[0118] In some examples of the present application, the first antibody is selected from antibodies that recognize non-carboxylated osteocalcin. As mentioned above, the first antibody complex refers to the antibody or antigen-binding fragment of any of the above examples being bound to magnetic microspheres through functional groups to form immunomagnetic beads. Since the antibody has a high affinity with its corresponding antigen, it can be bound to the antigen and fixed to the magnetic microspheres for detection.

[0119] In some examples of the present application, the magnetic microspheres are selected from composite microspheres formed by ferric oxide or ferroferric oxide magnetic nanoparticles and organic polymer materials. Because they have superparamagnetism, high specific surface area, modifiable functional groups and other properties, the inventors choose to immobilize antibodies or antigen-binding fragments thereof on their surfaces.

[0120] In some examples of the present application, the surface of the composite microsphere is modified to carry one or more active groups, and the active groups can be cross-linked with the amino group or carboxyl group of the non-carboxylated osteocalcin antibody through amide bonds to form magnetic microspheres coated with non-carboxylated osteocalcin antibodies.

[0121] In some examples of the present application, non-carboxylated osteocalcin antibodies (or osteocalcin antibodies) can also be directly or indirectly coupled to the surface of magnetic beads through their own amino or carboxyl groups, such as being coated on magnetic microspheres by the method of magnetic beads-streptavidin coupling-biotin-biotin carrier protein indirect coating, or they can be connected to magnetic particles in the reaction in the form of an antibody solution.

[0122] In some examples of the present application, the second antibody is selected from antibodies that recognize osteocalcin. As mentioned above, the second antibody complex refers to an antibody complex obtained by subjecting a commercial osteocalcin antibody to an immunolabeling technique (such as enzyme labeling, ferritin labeling, or colloidal gold labeling). In one example of the present application, the second antibody complex is obtained by enzyme labeling.

[0123] In some examples of the present application, the marker is coupled to the osteocalcin antibody via an amide bond to form a marker-osteocalcin antibody conjugate.

[0124] In some examples of the present application, the coupling method of the marker and the osteocalcin antibody can be obtained based on any method known in the art, for example, 2-Iminothiolane hydrochloride (2-IT), a commonly used activator in the art, is added to the osteocalcin antibody, and Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), a commonly used activator in the art, is added to the marker. The mixing ratio of the activated marker and the osteocalcin antibody is preferably 1:0.5 to 2, and can be optionally 1:0.5; 1:1; 1:1.5 or 1:2.

[0125] As mentioned above, immunolabeling technology is to label some substances that are both easy to measure and highly sensitive onto specific antigens or antibody molecules, and to display the properties and content of the antigens or antibodies in the reaction system through the enhanced amplification effect of these markers. In some examples of this application, the second antibody complex is mainly used for the localization analysis of antigens. In some cases, it can also be used to quantitatively detect antigens in samples mixed with a large number of other molecules. Since antibodies have a high affinity for their corresponding antigens, antibodies with easily recognizable markers can locate and analyze antigens, and are an ideal, rapid and inexpensive quantitative measurement method.

[0126] In some examples of the present application, the coupling treatment is performed by the following steps: coupling reaction of magnetic microspheres with a predetermined mass ratio and the first antibody in a MES buffer system to obtain a first antibody complex.

[0127] In some examples of the present application, the mass ratio of the first antibody to the magnetic microspheres is 1 to 20: 1000. Specifically, the mass ratio is optionally 1: 1000, 1: 500 or 1: 50. In some preferred examples of the present application, the concentration of the magnetic microspheres is 0.1-2 mg / ml, preferably 1 mg / ml.

[0128] In some examples of the present application, the coupling reaction time is selected from 5 to 8 hours (h), optionally 5h, 6h, 6.5h, 7h or 8h. In a preferred example of the present application, the coupling reaction time is 6.5 hours.

[0129] In some examples of the present application, the coupling reaction temperature is selected from 4 to 8° C., optionally 4° C., 5° C., 6° C., 7° C. or 8° C. In a preferred example of the present application, the coupling reaction temperature is 4° C.

[0130] In some examples of the present application, the detection method further comprises: using a calibrator to draw a standard curve of non-carboxylated osteocalcin concentration-luminescence value, wherein the calibrator comprises non-carboxylated osteocalcin with a predetermined concentration gradient.

[0131] Illustratively, the antibody or antigen-binding fragment thereof in any of the aforementioned examples is coupled to magnetic microspheres to prepare a first antibody complex, the antibody or antigen-binding fragment thereof in any of the aforementioned examples is labeled with alkaline phosphatase (ALP) to prepare a second complex, and a 9,10-dihydroacridine derivative at a concentration of 0.005%-0.05% or an adamantane derivative at a concentration of 0.005%-0.05% is used as a substrate solution. When the reaction occurs, the aforementioned substrate is catalytically cleaved under the action of alkaline phosphatase (ALP) to form an unstable excited intermediate. When the excited intermediate returns to the ground state, it emits photons to form a luminescent reaction, and the luminescence intensity of the reaction can be detected using a luminometer.

[0132] In some examples of the present application, the step of determining the content of non-carboxylated osteocalcin based on the luminescence intensity obtained after the contact treatment includes: performing a detection treatment on a standard substance to determine the luminescence intensity corresponding to different concentrations; wherein the calibrator contains non-carboxylated osteocalcin with a predetermined concentration gradient; drawing a non-carboxylated osteocalcin concentration-luminescence value standard curve based on the luminescence intensity corresponding to different concentrations; and obtaining the content of non-carboxylated osteocalcin in the sample to be tested based on the non-carboxylated osteocalcin concentration-luminescence value standard curve and the luminescence intensity obtained after the contact treatment.

[0133] In some other examples of the present application, the first antibody is selected from an antibody that recognizes osteocalcin. The preparation process of the first antibody complex is the same as above and will not be repeated here.

[0134] In some other examples of the present application, the second antibody is selected from antibodies that recognize uncarboxylated osteocalcin. The preparation process of the second antibody complex is the same as above and will not be repeated here.

[0135] In one example of the present application, the non-carboxylated osteocalcin concentration-luminescence value standard curve is obtained by the following method, including:

[0136] (1) Immune reaction: 50 μl of calibrator or quality control products of different concentrations, 50 μl of first antibody complex, and 50 μl of second antibody complex were added to the reaction tubes in sequence, and mixed and incubated at 37°C for 10 min;

[0137] (2) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μl of cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0138] (3) Reading: Add 200 μl of luminescent substrate solution, and use the fully automatic chemiluminescence immunoassay analyzer SMART 500H to measure the relative luminescence intensity after alkaline phosphatase catalyzes the substrate to emit light;

[0139] (4) A four-parameter equation was used to fit the detected values ​​to obtain a standard curve of non-carboxylated osteocalcin concentration-luminescence value.

[0140] For ease of understanding, the above detection method is described in detail by taking the non-carboxylated osteocalcin chemiluminescence immunoassay as an example.

[0141] Step 1: coating the non-carboxylated osteocalcin antibody of any of the above embodiments on the surface of magnetic microparticles to prepare a non-carboxylated osteocalcin antibody magnetic microsphere buffer solution;

[0142] Step 2: preparing a marker-labeled osteocalcin solution;

[0143] Step 3: Mix the sample to be tested, the solution in step 1, and the solution in step 2 in proportion and perform an immune reaction;

[0144] Step 4: After the reaction is complete, the magnetic microparticles are collected by a magnetic field, and a substrate that makes the marker in step 2 emit light is added to obtain a standard curve of non-carboxylated osteocalcin concentration-luminescence value;

[0145] Step 5: Calculate the non-carboxylated osteocalcin content according to the standard curve.

[0146] The above detection kit and detection method have the following beneficial effects:

[0147] The present application adopts a sandwich reaction mode, and utilizes the principle of combining chemiluminescence detection technology with magnetic microsphere immunoseparation technology to quantitatively detect the content of non-carboxylated osteocalcin in human serum or plasma samples, thereby ensuring the sensitivity of the detection. Since the experiment adopts the sandwich method, it is pollution-free, highly specific, simple to operate, and has low requirements for sample pretreatment, and can rapidly and high-throughput detect large quantities of samples, which is convenient for clinical reagent application. The present application provides a more accurate, convenient and quick method for clinical detection of non-carboxylated osteocalcin in samples.

[0148] Table 1

[0149]

[0150]

[0151]

[0152] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0153] Example 1: Synthesis of non-carboxylated osteocalcin peptides, carboxylated osteocalcin peptides and full-length osteocalcin antigen

[0154] The full-length osteocalcin antigen sequence (Table 1, SEQ ID NO: 15), carboxylated osteocalcin, and non-carboxylated osteocalcin protein sequences (Table 1, SEQ ID NOs: 16-18) were synthesized by Hypotec Biotechnology Co., Ltd.

[0155] Example 2: Identification of uncarboxylated osteocalcin

[0156] This example uses a conventional laboratory method to detect the antigenic activity of non-carboxylated osteocalcin. The specific steps are as follows:

[0157] The non-carboxylated osteocalcin protein was coated on the ELISA plate at 1 μg / ml, the purified non-carboxylated osteocalcin antibody was used as the primary antibody of the indirect ELISA method, and the HRP-labeled goat anti-rat antibody was used as the secondary antibody. TMB was used as the color developing solution, and then 1M H2SO4 was used to terminate the reaction. The OD value of the microplate reader was 450 The antigen activity of non-carboxylated osteocalcin was compared, and it was found that the antigen activity of non-carboxylated osteocalcin was higher (Table 2).

[0158] Table 2

[0159] sample <![CDATA[OD 450 ]]> Uncarboxylated osteocalcin concentration (1 μg / ml) 0.928 blank 0.028

[0160] Example 3: Immunization of BALB / c mice with non-carboxylated osteocalcin protein

[0161] In this example, the non-carboxylated osteocalcin protein synthesized in Example 1 was used to immunize BALB / c mice, and the antibody serum titer of the mice was detected.

[0162] The specific steps are as follows:

[0163] BALB / c mice aged 6 to 8 weeks were selected for the following immunization procedure: for the first immunization, 25 μg of non-carboxylated osteocalcin was mixed with an equal amount of Freund's complete adjuvant and injected subcutaneously at multiple points after emulsification; 14 days after the first immunization, 12.5 μg of non-carboxylated osteocalcin was mixed with Freund's incomplete adjuvant and emulsified for booster immunization. 14 days after the second immunization, 12.5 μg of non-carboxylated osteocalcin was mixed with Freund's incomplete adjuvant and emulsified for booster immunization. 14 days after the third immunization, blood was collected and serum was separated. ELISA plates were coated with 1 μg / mL non-carboxylated osteocalcin, and indirect ELISA tests were performed to determine the serum titer. The results showed that the titer of the prepared mouse antiserum was 1:72900. The typical test results of immunized mouse serum are shown in Table 3.

[0164] Table 3

[0165]

[0166]

[0167] Example 4: Cell fusion

[0168] In Example 3, cell fusion was performed 3 days after the booster immunization of mice. After removing the eyeballs of the mice to collect blood, the mice were killed by dislocation, placed in a 70% alcohol bottle for 2 minutes, and then fixed on a foam board in a biosafety cabinet. The abdominal skin was untied to find the spleen, which was removed with forceps and gently ground into a 200-mesh stainless steel filter. The cells were gently rinsed with DMEM culture medium (Thermo, 11965092), and then centrifuged at 200g for 10 minutes at room temperature. The supernatant was discarded and set aside. When preparing feeder cells, the mice were killed by dislocation, placed in a 70% alcohol bottle for 2 minutes, and then fixed on a foam board in a biosafety cabinet. The abdominal skin was untied, and PBS was sucked up with a syringe and gently injected into the peritoneum. The liquid containing the feeder cells was washed out from the other side, and then centrifuged at 200g for 10 minutes at room temperature. The supernatant was discarded and set aside. 2.0×10 7 FO myeloma cells and 2.0×10 8The spleen cells were mixed, centrifuged at 200g for 10 minutes, the supernatant was discarded, and the mixture was gently shaken to mix. In a 37°C water bath, 1 ml of a 50% PEG-1450 (Merk, P1458) aqueous solution was added dropwise within 90 seconds, followed by 20 mL of DMEM culture medium. The mixture was centrifuged at 200g for 10 minutes, the supernatant was discarded, and the washing was repeated. The mixture was centrifuged at 200g for 10 minutes, the supernatant was discarded, and the hybridoma cells were obtained. The cells were plated into 10 96-well culture plates with 150 μL per well. 10,000 cells / well of feeder layer cells were added to the above 10 96-well cell culture plates, 100 μL per well, and the culture plates were marked and placed in a cell culture incubator at 37°C containing 5% CO2 for culture. HAT screening medium (Merk, H0262) was added on the second day, and a large number of tumor cells died within 1-2 days of HAT selection culture. After 3-4 days, the tumor cells disappeared and hybrid cells formed small colonies. After 7-10 days of HAT selection culture medium, HT culture medium (Merk, H0137) should be used, and then maintained for another 2 weeks, and then 20% FBS (ExCell, FSP500) DMEM culture medium was used for continued culture. During the above selection culture period, when the hybridoma cells covered 1 / 10 of the bottom area of ​​the well, specific antibodies could be detected to screen out the desired hybridoma cell lines. During the selection culture period, the culture medium was generally changed every 2-3 days.

[0169] Example 5: Screening and subcloning of positive hybridoma cell lines

[0170] First, the optimal coating amount of non-carboxylated osteocalcin as an antigen was determined by the founder experiment. 0.5, 1.0, 2.0, and 4.0 μg of non-carboxylated osteocalcin were coated on a 96-well plate, and 6 wells of each concentration were set as 3 positive and 3 negative. Founder titration was performed with positive serum from mice immunized with non-carboxylated osteocalcin at different dilutions, and negative serum from non-immunized mice was used as a negative control. 96-well ELISA plates were coated with 0.5 μg of purified non-carboxylated osteocalcin per well, overnight at 4°C; washed twice with PBST; 200 μL of 1% BSA in PBS was added to each well, blocked at room temperature for 2 hours, and then placed on trifold paper and patted dry; sample addition: 0.1 mL of the sample to be tested was added to the reaction well, incubated at 37°C for 1 hour, and then washed, and blank wells (no sample added), negative control wells, and positive control wells were made at the same time. 0.1 mL of newly diluted antibody was added to each reaction well, incubated at 37°C for 1 hour, and then washed 3 times. Add enzyme-labeled secondary antibody: Add 0.1 mL of freshly diluted enzyme-labeled antibody to each reaction well. Incubate at 37°C for 1 hour and wash 3 times. Add substrate solution for color development: Add 0.1 mL of TMB substrate solution to each reaction well and let stand at room temperature for 10 minutes. Add 0.1 mL of 1M H2SO4 to each reaction well. Measure the OD value to determine the result, and use an enzyme-labeled instrument to measure the absorbance value (A450) at 450 nm. A value that is 2.1 times or more of the negative control OD value is considered positive (calculated after adjusting the blank control well to zero). Select the hybridoma cell monoclonal clone that is resistant to non-carboxylated osteocalcin.

[0171] According to the above method, the positive hybridoma cells obtained by screening are subcloned, and the original wells are diluted with HAT selection medium by limiting dilution method and then redistributed into 96-well culture plates, and then the morphology and number of cells are observed. The cells are adjusted to 3-10 cells / mL. Take the cell culture plate with feeder cell layer prepared the day before, and add 100 μL of diluted cells to each well. Culture statically in a 37°C, 5% CO2 incubator. Change the medium on the 7th day, and change the medium once every 2-3 days thereafter. Cell clones can be seen on the 8th to 9th day, and the antibody activity is detected in time. The cells in the positive wells are transferred to a 24-well plate for expansion and culture. Each clone should be frozen as soon as possible, and finally the hybridoma cell line with clone number G069 is selected for antibody production.

[0172] Example 6: Preparation of monoclonal antibodies in large quantities and determination of antibody titer

[0173] (1) Large-scale preparation of monoclonal antibodies

[0174] 8-week-old BALB / C mice were intraperitoneally injected with 0.5 mL of Freund's incomplete adjuvant. Two weeks later, 1 × 10 6Hybridoma cells can produce ascites 7 to 10 days after inoculation. Closely observe the health status and ascites signs of the animals. When ascites is as much as possible and before the mice die, kill the mice and use a dropper to suck the ascites into a test tube. 5 to 10 ml of ascites can be obtained from one mouse. Ascites can also be extracted with a syringe and can be collected repeatedly several times. The ascites obtained is centrifuged at 3000g for 10 minutes, the upper layer of fat and the bottom sediment are discarded, the supernatant is collected and distributed at -20℃, the ascites supernatant is thawed and equilibrated to room temperature, and 1 / 10 volume of 1M Tris-HCl pH 8.0 is added to adjust the sample pH to 8.0. The protein G affinity column was balanced with 20 column volumes of 100mM Tris-HCl at pH 8.0, and the ascites supernatant after adjusting the pH to 8.0 was loaded onto the column, followed by washing with 20 column volumes of 100mM Tris-HCl at pH 8.0, and finally eluting the antibody with 100mM Glycine-HCL pH 2.5. The antibody eluate was added to a concentrator tube (Millipore, UFC801008, 10K) and centrifuged at room temperature for 20 minutes at 3000×g in a centrifuge (Xiangyi, L550). Batch centrifuged until the solution volume reached 1ml / concentrator tube (2 tubes), 4mL of 10mM PBS pH 7.4 buffer was added, and centrifuged at room temperature for 20 minutes at 3000×g. Repeat the centrifugation 3 times to make the antibody buffer 10mM PBS pH 7.4, and add 10mM PBS pH 7.4 to a total volume of 10mL. Finally, 2 mL / tube of the concentrated antibody solution was dispensed into centrifuge tubes and stored at -80° C. The antibody concentration was determined using a BCA kit (Solabo, PC0020), and the concentration of the purified monoclonal antibody was 2.9 mg / mL.

[0175] (2) Antibody titer determination

[0176] The titer of non-carboxylated osteocalcin antibody G069 was detected by ELISA indirect method. Non-carboxylated osteocalcin was diluted with PBS and coated in 96-well ELISA plates at 0.2 μg / mL and 100 μL / well. After overnight at 4°C, the ELISA plates were washed twice with PBST solution, 300 μL / well each time, and patted dry after washing. The ELISA plates were blocked with 1% BSA PBS solution, 200 μL / well, at room temperature for 2 hours, and patted dry after blocking; non-carboxylated osteocalcin antibody G069 diluted to 20 ng / mL with PTB was added, reacted in a 37°C incubator for 1 hour, and the ELISA plates were washed twice with PBST solution, 300 μL / well each time. Patted dry after washing. HRP-labeled goat anti-mouse antibody diluted 5000 times with PTB was added, reacted in a 37°C incubator for 1 hour, and the ELISA plates were washed twice with PBST solution, 300 μL / well each time. Patted dry after washing. TMB substrate solution was added, 100 μL / well was reacted at room temperature for 10 minutes, and 100 μL / well of 1M H2SO4 was added to terminate the reaction. The absorbance value (A450) was measured at 450 nm using an ELISA reader. The results are shown in Table 4, and it can be seen that the titer of the purified antibody is 1:729000.

[0177] Table 4

[0178] Antibody dilution factor OD450 1000 1.530 3000 1.393 9000 1.283 27000 1.169 81000 0.904 243000 0.572 729000 0.262 Background 0.048

[0179] Example 7: Sequence analysis of monoclonal antibodies

[0180] (1) Monoclonal antibody subtype identification

[0181] The hybridoma cell line G069 was cultured in a 10 cm diameter cell culture dish (37°C, 5% CO2) using DMEM medium (GIBCO, #C11995500BT) supplemented with 10% serum. After 7 days of culture, the cells were transferred to a 15 ml centrifuge tube and 4 × 10 6 After centrifugation at 200 g for 5 minutes, the supernatant was discarded, and the centrifuge tube was inverted to drain the liquid in the tube. The cells in the tube were synthesized into cDNA using the reverse transcription kit (Qiagen, 74134) of QIAGEN Company.

[0182] The antibody subtype is determined by PCR using antibody subtype-specific primers. The above-synthesized cDNA is used as a PCR reaction template. PCR reaction solution system: TAKARA Ex Taq (5U / μL, TAKARA, RR001B), 0.25μL; 10×Ex Taq Buffer, 5μL; dNTP mixture (2.5mM each), 4μL; template cDNA, 1μL; upstream primer (100μM), 1μL; downstream primer (100μM), 1μL; add double distilled water to a total volume of 50μL. PCR reaction temperature program: 94°C for 5 minutes for pre-denaturation, temperature cycle 30 times (94°C for 1 minute, 57°C for 1 minute, 72°C for 1 minute), and 72°C for 10 minutes for extension. After the reaction, 10μL of each PCR product was loaded on a 1% agarose gel for electrophoresis. The electrophoresis pattern is shown as follows. Figure 1 The order of samples added to each lane is shown in Table 6. The subtype of the antibody can be inferred from the PCR product results (Table 5). The heavy chain of the monoclonal antibody G069 obtained in the present application is IgG1, and the light chain is kappa.

[0183] Table 5

[0184]

[0185]

[0186] Note: S=C or G, M=A or C, R=A or G, and W=A or T.

[0187] Table 6

[0188] Lanes PCR primers Antibody subtype specificity 1 PCR products of primers F-VH and R-VH 1 IgG1 heavy chain 2 PCR products of primers F-VH and R-VH 2A IgG2A heavy chain 3 PCR products of primers F-VH and R-VH 2B IgG2B heavy chain 4 PCR products of primers F-VH and R-VH 3 IgG3 heavy chain 5 PCR products of primers F-VH and R-VK IgKappa light chain 6 PCR products of primers F-VL and R-VL1 IgLambda1 light chain 7 PCR products of primers F-VL and R-VL2 IgLambda2 light chain 8 DNA molecular weight standard (full gold, DNA MarkerII, #BM411) N / A

[0189] (2) Sequencing of the variable region (V region) of the hybridoma cell line G069

[0190] The fragment obtained after PCR amplification of the V region of the antibody of cell line G069 (see above) was cut from the agarose gel and extracted with a DNA extraction kit (Qiagen, 74134). The extracted DNA fragment was linked to the pEASY-T1 cloning vector and transformed into Trans1-T1 competent cells (Transgen, CT101-1). The transformed bacterial colonies were picked into LB culture medium and DNA sequencing was performed after overnight culture. The nucleotide sequence of the light chain variable region (V region) of the non-carboxylated osteocalcin antibody (G069) provided in the present application is shown in SEQ ID NO: 12, and the nucleotide sequence of the heavy chain variable region (V region) is shown in SEQ ID NO: 11.

[0191] Example 8: Identification of the specificity of antibody G069 in detecting uncarboxylated osteocalcin

[0192] The ability of antibody G069 to specifically detect free uncarboxylated osteocalcin was evaluated by ELISA. In this experiment, uncarboxylated osteocalcin peptides and carboxylated osteocalcin peptides were diluted in PBS as antigens and coated in 96-well ELISA plates at a coating concentration of 1 μg / mL and 0.5 μg / mL, respectively, in a volume of 100 μL / well. After overnight coating at 4°C, the ELISA plates were washed twice with PBST solution, 300 μL / well each time. After washing, the plates were patted dry and blocked with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. After patting dry, antibody G069 (diluted to 10 ng / mL with PTB) was added to the blocked ELISA plates, 100 μL / well, and reacted in a 37°C incubator for 1 hour. After patting dry, the plates were washed 3 times with PBST, 300 μL / well each time. Pat dry, add HRP-labeled goat anti-mouse antibody diluted 5000 times with PTB to the ELISA plate, and react in a 37°C incubator for 1 hour. Wash the plate 3 times with PBST, 300 μL / well. Pat dry, add TMB substrate solution to the ELISA plate, 100 μL / well, at room temperature for 10 minutes, then add 100 μL / well of 1M H2SO4 to terminate the reaction. Use an ELISA reader to measure the absorbance (A450) at 450 nm. The experimental results are shown in Table 7, indicating that antibody G069 has good specificity for detecting non-carboxylated osteocalcin.

[0193] Table 7

[0194] Antigen concentration (ng / ml) Uncarboxylated osteocalcin peptide Carboxylated osteocalcin peptide 1000 1.683 0.098 500 0.935 0.086 Background 0.061 0.063

[0195] Example 9: Application of the ELISA kit prepared using antibody G069 in detecting uncarboxylated osteocalcin in human serum

[0196] (1) Horseradish peroxidase (HRP) labeling of antibody G069 and identification of the labeled product

[0197] 0.5 mL of antibody G069 (20 nmol, 3 mg) was added to a dialysis bag (10 KDa, 1 cm width) and dialyzed in 2 L of 10 mM PBS solution (pH 7.4) at 4 ° C overnight. The next day, the dialysis bag containing the antibody solution was placed in 1 L of 10 mM carbonate buffer (pH 9.5) and dialyzed for 2 hours at room temperature to prepare for coupling with activated HRP.

[0198] At the same time, use an analytical balance to accurately weigh 1 mg of HRP, add 0.2 mL of ultrapure water to dissolve, and make the HRP concentration 5 mg / mL. Add 40 μl of 0.1M NaIO4 to the above HRP solution, place it on a horizontal shaker, and react (activate) at room temperature in the dark for 20 minutes. Add the activated HRP solution to a dialysis bag (10KDa, width 1 cm) and dialyze it in 2L 1mM sodium acetate buffer (pH 4.4) at 4°C overnight. Carefully aspirate the dialyzed HRP solution and transfer it to a new 1.5 mL centrifuge tube, add 1 / 10 volume of 0.2M carbonate buffer to raise the pH of the activated HRP solution to 9.0-9.5.

[0199] Mix the above antibodies and HRP (for coupling reaction), place on a horizontal shaker, and react at room temperature in the dark for 4 hours. After the coupling reaction is completed, add 10ul (pre-cooled ultrapure water) freshly prepared NaBH4, and terminate the reaction at 4°C in the dark overnight. Move the antibody solution after the coupling reaction is terminated to a dialysis bag (10KDa, width 1cm), stir and dialyze at room temperature for 2 hours. Finally, transfer the solution to a brown centrifuge tube and store at 4°C.

[0200] (2) Detection of uncarboxylated osteocalcin in human serum using an ELISA kit prepared using antibody G069

[0201] In this experiment, osteocalcin antibody (SCBT, sc-74495) was diluted to 1 μg / mL with PBS, and then 100 μL / well was coated in a 96-well ELISA plate (overnight at 4°C). The plate was washed twice with 300 μL / well PBST. Pat dry, block the ELISA plate with PBS solution containing 1% BSA, 200 μL / well, at room temperature for 2 hours. Pat dry, add 1000-fold diluted HRP-labeled antibody G069 (diluted with PTB) solution 25ul / well to the ELISA plate, and then add different concentrations of human serum samples (serum of patients with clinically confirmed bone-related diseases was selected as the sample to be tested, and serum of healthy people was used as the negative sample), 75 μL / well, and reacted in a 37°C incubator for 45 minutes. Wash the plate 3 times with PBST, 300 μL / well each time. Pat dry, add TMB substrate solution, 100 μL / well, and react at room temperature for 10 minutes. Then, 100 μL / well of 1M H2SO4 was added to terminate the reaction, and the absorbance (A450) was measured at 450 nm using an ELISA reader. The results are shown in Table 8, indicating that the ELISA kit prepared using antibody G069 can efficiently detect non-carboxylated osteocalcin in human serum.

[0202] Table 8

[0203] Patient serum samples <![CDATA[OD 450 ]]> <![CDATA[OD 450(空白) ]]> Patient 1 0.913 0.059 Patient 2 0.845 0.037 Patient 3 0.986 0.082 Patient 4 0.275 0.093 Patient 5 0.485 0.081

[0204] Example 10: Detection of uncarboxylated osteocalcin based on chemiluminescence

[0205] This example uses the non-carboxylated osteocalcin antibody prepared in the previous example to design a detection kit. The magnetic microsphere separation chemiluminescence immunoassay method is used as an example. The detection principle is as follows: Figure 2 As shown, the specific steps of the kit for detecting the content of non-carboxylated osteocalcin in the sample to be tested are demonstrated.

[0206] Instrument: The company's self-developed chemiluminescence detector;

[0207] Reagents: labeled alkaline phosphatase (ALP) was purchased from BBI, UK, model: ALPI12G; SMCC was purchased from thermofisher scientific, item number: 22360; 2-IT was purchased from thermo fisher scientific, CAS: 4781-83-3; item number: 26101; carboxyl-modified microparticles were purchased from thermo fisher scientific; EDC was purchased from SIMGA, CAS: 25952-53-8, item number: E7750; the antibodies were the G069 antibody prepared in the above example and the commercial osteocalcin antibody, purchased from R&D Systems, Inc., item number MAB11327; the luminescent substrate came from the company's self-developed reagents; the remaining reagents were conventional products purchased from the market.

[0208] Experiment 1: Magnetic microspheres labeled with non-carboxylated osteocalcin antibody

[0209] Take 20 mg of carboxyl-modified microparticle solution, and let the magnetic microspheres with superparamagnetism, uniform particle size, and carboxyl (COOH-) active groups on the surface settle under the action of a magnetic field (magnetic separation) for 10 minutes, remove the supernatant, and wash the settled magnetic microspheres three times with an activation buffer having a molar concentration of 0.05 M (2-(N-morpholine)ethanesulfonic acid) MES, pH 6.0 buffer, each time using 2 ml.

[0210] The washed magnetic microspheres were fully suspended with 1.0 ml of activation buffer (2-(N-morpholinoline)ethanesulfonic acid) MES, pH 6.0, and then the activator 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) was added and suspended at room temperature for 30 minutes. The reaction molar concentration of EDC was 7.5 mM.

[0211] Take 1.0 mg of uncarboxylated osteocalcin antibody and concentrate it to 2.5 mg / mL.

[0212] The non-carboxylated osteocalcin antibody concentrated to 2.5 mg / mL was added to 20 mg of the activated magnetic microsphere solution according to 1.0 mg of the non-carboxylated osteocalcin-coupled carrier protein antigen, and the mixture was gently shaken to mix well. The mixture was reacted at 4° C. under suspension conditions for 6.5 hours, so that the non-carboxylated osteocalcin antibody was covalently coupled to the surface of the magnetic microspheres. The mixture was named reagent A.

[0213] Experiment 2: Alkaline phosphatase labeled osteocalcin antibody

[0214] 1.0 mg of osteocalcin antibody was concentrated to 2.5 mg / mL, and 5 μL of activator 2-Iminothiolane hydrochloride (2-IT) solution with a concentration of 13.76 mg / mL was added, and reacted at room temperature for 15 minutes. The activated antibody was collected after desalting using a Sephadex G25 gel column.

[0215] 1.2 mg of alkaline phosphatase was concentrated to 2.5 mg / mL, and 12 μL of activator Succinimidyl4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) solution with a concentration of 6.69 mg / mL was added, and the mixture was reacted at room temperature for 15 minutes. The activated alkaline phosphatase was collected after desalting using a Sephadex G25 gel column.

[0216] The activated osteocalcin antibody and alkaline phosphatase were mixed at a ratio of 1.0 mg of osteocalcin antibody to 1.0 mg of alkaline phosphatase, and the mixture was allowed to react at 4°C for 18 hours.

[0217] The unconnected osteocalcin antibody 2 and alkaline phosphatase were removed by separation and purification using a Supperdex200 gel chromatography column, and the connection product was stored at 4°C and named as reagent B.

[0218] Experiment 3: Chemiluminescent immunoassay for separation of uncarboxylated osteocalcin using magnetic microspheres

[0219] (1) Immunoreaction: Take 50 μl of the calibrator or quality control and add 50 μl of reagent A prepared in Experiment 1 and 50 μl of reagent B prepared in Experiment 2 into the reaction tubes, mix and incubate at 37°C for 10 min.

[0220] (2) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μl of cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0221] (3) Reading: Add 200 μl of luminescent substrate solution, and use a self-developed chemiluminescence detector to measure the relative luminescence intensity (RLU) after alkaline phosphatase catalyzes the substrate to emit light;

[0222] (4) A four-parameter equation was used to fit the detected values ​​to obtain a standard curve of non-carboxylated osteocalcin concentration-luminescence value.

[0223] (5) Add 50 μl of the sample to be tested, 50 μl of reagent A prepared in Experiment 1, and 50 μl of reagent B prepared in Experiment 2 into the reaction tube in sequence, and incubate at 37°C for 15 min;

[0224] (6) Magnetic separation: allow the magnetic microspheres to settle in a magnetic field, remove the supernatant, add 200-500 μl of a cleaning solution, remove the magnetic field, and then allow the magnetic microspheres to settle in a magnetic field again, and remove the supernatant; repeat this process 2-4 times to remove unbound antibodies and impurities;

[0225] (7) Reading: Add 200 μl of luminescent substrate solution, and use a self-developed chemiluminescence detector to measure the relative luminescence intensity (RLU) after ALP catalyzes the substrate to emit light;

[0226] (8) The luminescence intensity of the sample to be tested is compared with the standard curve of step (4), and the content of uncarboxylated osteocalcin in the sample to be tested can be calculated using a four-parameter equation fitting.

[0227] In summary, the monoclonal antibody of non-carboxylated osteocalcin prepared by the present application has the characteristics of high affinity and specificity. The non-carboxylated osteocalcin detection kit prepared based on the antibody can be used for rapid detection of non-carboxylated osteocalcin content in serum or plasma samples, with high sensitivity, strong specificity, simple operation and low pre-treatment requirements for samples. By being used in conjunction with a fully automatic chemiluminescence analyzer, the operating steps are greatly simplified, the detection speed and detection flux are increased, the detection efficiency is improved, and the errors caused by human operation are avoided at the same time.

[0228] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0229] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. An antibody or an antigen-binding fragment thereof, characterized in that: include: Heavy chain variable region; The heavy chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 1 to 3 or an amino acid sequence having at least 80% identity thereto.

2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody or antigen-binding fragment thereof comprises: The heavy chain variable region CDR1 sequence as shown in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity with SEQ ID NO: 1; The heavy chain variable region CDR2 sequence as shown in the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity with SEQ ID NO: 2; The heavy chain variable region CDR3 sequence is shown in the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that has at least 80% identity to SEQ ID NO: 3, respectively.

3. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: Further including: light chain variable region; The light chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 4 to 6 or an amino acid sequence having at least 80% identity thereto; Optionally, the antibody or antigen-binding fragment thereof comprises: The light chain variable region CDR1 sequence as shown in the amino acid sequence of SEQ ID NO:4 or an amino acid sequence that is at least 80% identical to SEQ ID NO:4; The light chain variable region CDR2 sequence as shown in the amino acid sequence of SEQ ID NO:5 or an amino acid sequence that is at least 80% identical to SEQ ID NO:5; The light chain variable region CDR3 sequence is shown in the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence that has at least 80% identity with SEQ ID NO:

6.

4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that: The antibody or antigen-binding fragment thereof further comprises a heavy chain framework region sequence, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody or a mutant thereof; Preferably, at least a portion of the heavy chain framework region sequence is derived from a murine antibody; Optionally, the heavy chain variable region amino acid sequence is as shown in SEQ ID NO:7; Optionally, the antibody or antigen-binding fragment thereof further contains a light chain framework region sequence, at least a portion of which is derived from at least one of a murine antibody, a rabbit antibody, a primate antibody or a mutant thereof; Preferably, at least a portion of the light chain framework sequence is derived from a murine antibody; Optionally, the light chain variable region amino acid sequence is as shown in SEQ ID NO:

8.

5. The antibody or antigen-binding fragment thereof according to claim 4, characterized in that: The antibody or antigen-binding fragment thereof further comprises a heavy chain constant region, at least a portion of which is derived from at least one of a mouse antibody, a rabbit antibody, a primate antibody or a mutant thereof; Preferably, at least a portion of the heavy chain constant region sequence is derived from a murine antibody; Optionally, the heavy chain constant region amino acid sequence is as shown in SEQ ID NO:9; Optionally, the antibody or antigen-binding fragment thereof further contains a light chain constant region sequence, at least a portion of which is derived from at least one of a murine antibody, a rabbit antibody, a primate antibody or a mutant thereof; Preferably, at least a portion of the light chain constant region sequence is derived from a murine antibody; Optionally, the light chain constant region amino acid sequence is as shown in SEQ ID NO:

10.

6. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody comprises at least one selected from a polyclonal antibody and a monoclonal antibody; or The antigen-binding fragment comprises at least one selected from the group consisting of a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a F(ab)2 fragment, a Fv fragment, a scFv fragment, a scFv-Fc fusion protein, a scFv-Fv fusion protein and a minimum recognition unit; Preferably, the antibody is a monoclonal antibody.

7. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6; Optionally, the nucleic acid molecule is DNA.

8. An expression vector, characterized in that Carrying the nucleic acid molecule according to claim 7.

9. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, characterized in that: include: Introducing the expression vector of claim 8 into a cell; Cultivating the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof; Optionally, the cell is a eukaryotic cell.

10. A recombinant cell, characterized in that The recombinant cell carries the nucleic acid molecule of claim 7 or the expression vector of claim 8.

11. An immunoconjugate, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8, or the recombinant cell according to claim 10; Optionally, the immunoconjugate further comprises a therapeutic agent.

12. A composition, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, carrying the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10 or the immunoconjugate according to claim 11.

13. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10, the immunoconjugate according to claim 11 or the composition according to claim 12 in the preparation of a medicament for treating or preventing non-carboxylated osteocalcin-mediated related diseases.

14. The use according to claim 13, characterized in that The non-carboxylated osteocalcin-mediated related diseases include liver disease, diabetes, rheumatoid arthritis, hypoparathyroidism, peripheral arterial and coronary atherosclerosis, bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity and bone tumors.

15. A drug, characterized in that include: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8, the recombinant cell according to claim 10, the immunoconjugate according to claim 11 or the composition according to claim 12, wherein the drug is used to treat or prevent related diseases mediated by non-carboxylated osteocalcin.

16. The drug according to claim 15, characterized in that The non-carboxylated osteocalcin-mediated related diseases include liver disease, diabetes, rheumatoid arthritis, hypoparathyroidism, peripheral arterial and coronary atherosclerosis, bone trauma, osteomalacia, primary hyperthyroidism, menopausal syndrome, premature ovarian failure, osteoporosis, abnormal calcium metabolism, calcium deficiency, obesity and bone tumors.

17. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 in the preparation of a kit for detecting uncarboxylated osteocalcin.

18. A kit, characterized in that: The kit comprises: The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.

19. The kit according to claim 18, characterized in that Further including: At least one of magnetic microspheres, biomarkers, biomarker substrates, buffers, calibrators, and quality control products; Optionally, the particle size of the magnetic microspheres is selected from 0.5-10 μm, preferably 3-8 μm; Optionally, the biomarker includes at least one of a biological enzyme, a fluorescein, and a chemiluminescent marker; Optionally, the biological enzyme is selected from at least one of horseradish peroxidase and alkaline phosphatase; Optionally, the fluorescein is selected from at least one of fluorescein isothiocyanate, tetraethylrhodamine and tetramethylrhodamine isothiocyanate; Optionally, the chemiluminescent marker is selected from at least one of acridinium ester, terpyridine ruthenium, isoluminol or a derivative thereof; Optionally, the buffer comprises at least one selected from the group consisting of a phosphate buffer, a carbonate buffer, a Tris buffer and a citrate buffer.

20. A method for detecting uncarboxylated osteocalcin, characterized in that: include: The test sample is subjected to a detection treatment using the kit according to claim 18 or 19, so as to determine the content of the non-carboxylated osteocalcin in the test sample.

21. The method according to claim 20, characterized in that The detection process includes: The magnetic microspheres are coupled to the first antibody to obtain a first antibody complex; labeling the second antibody with a biomarker to obtain a second antibody complex; Mixing the sample to be tested, the first antibody complex and the second antibody complex; contacting the mixed treatment product with a biomarker substrate, wherein the biomarker has an activity of catalyzing the luminescence of the biomarker substrate; Determining the content of uncarboxylated osteocalcin in the sample to be tested based on the luminescence intensity obtained after the contact treatment; in, The first antibody and the second antibody independently recognize uncarboxylated osteocalcin and osteocalcin, respectively; Optionally, the antibody that recognizes uncarboxylated osteocalcin is selected from the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.

22. The method according to claim 21, characterized in that The coupling treatment is carried out by the following steps: Carrying out a coupling reaction between the magnetic microspheres and the first antibody at a predetermined mass ratio in a MES buffer system to obtain the first antibody complex; Optionally, the mass ratio of the first antibody to the magnetic microspheres is 1 to 20:1000; Optionally, the coupling reaction time is selected from 5 to 8 hours, preferably 6.5 hours; Optionally, the coupling reaction temperature is selected from 4 to 8°C; preferably 4°C.

23. The method according to claim 20, characterized in that The detection method further comprises: Draw a non-carboxylated osteocalcin concentration-luminescence value standard curve using a calibrator, wherein the calibrator comprises non-carboxylated osteocalcin with a predetermined concentration gradient; Optionally, the step of determining the content of uncarboxylated osteocalcin based on the luminescence intensity obtained after the contact treatment comprises: Performing detection processing on the standard substance to determine the luminescence intensity corresponding to different concentrations; wherein the calibrator contains non-carboxylated osteocalcin with a predetermined concentration gradient; Draw a non-carboxylated osteocalcin concentration-luminescence value standard curve based on the luminescence intensity corresponding to different concentrations; Based on the non-carboxylated osteocalcin concentration-luminescence value standard curve and the luminescence intensity obtained after the contact treatment, the non-carboxylated osteocalcin content in the sample to be tested is obtained.

Citation Information

Patent Citations

  • Recombinant chicken osteocalcin maturation protein monoclonal antibody and application thereof

    CN102154217A